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Insulin induces drug resistance in melanoma through activation of the
PI3K/Akt pathway
Abstract
Introduction: There is currently no curative treatment for melanoma once the disease spreads beyond the
original site. Although activation of the PI3K/Akt pathway resulting from genetic mutations and epigenetic
deregulation of its major regulators is known to cause resistance of melanoma to therapeutic agents, including
the conventional chemotherapeutic drug dacarbazine and the Food and Drug Administration-approved
mutant BRAF inhibitors vemurafenib and dabrafenib, the role of extracellular stimuli of the pathway, such as
insulin, in drug resistance of melanoma remains less understood. Objective: To investigate the effect of insulin
on the response of melanoma cells to dacarbazine, and in particular, the effect of insulin on the response of
melanoma cells carrying the BRAFV600E mutation to mutant BRAF inhibitors. An additional aim was to
define the role of the PI3K/Akt pathway in the insulin-triggered drug resistance. Methods: The effect of
insulin on cytotoxicity induced by dacarbazine or the mutant BRAF inhibitor PLX4720 was tested by pre-
incubation of melanoma cells with insulin. Cytotoxicity was determined by the MTS assay. The role of the
PI3K/Akt pathway in the insulin-triggered drug resistance was examined using the PI3K inhibitor LY294002
and the PI3K and mammalian target of rapamycin dual inhibitor BEZ-235. Activation of the PI3K/Akt
pathway was monitored by Western blot analysis of phosphorylated levels of Akt. Results: Recombinant
insulin attenuated dacarbazine-induced cytotoxicity in both wild-type BRAF and BRAFV600E melanoma
cells, whereas it also reduced killing of BRAFV600E melanoma cells by PLX4720. Nevertheless, the
protective effect of insulin was abolished by the PI3K and mTOR dual inhibitor BEZ-235 or the PI3K
inhibitor LY294002. Conclusion: Insulin attenuates the therapeutic efficacy of dacarbazine and PLX4720 in
melanoma cells, which is mediated by activation of the PI3K/Akt pathway and can be overcome by PI3K
inhibitors.
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Introduction: There is currently no curative treatment for melanoma once the disease spreads 
beyond the original site. Although activation of the PI3K/Akt pathway resulting from genetic 
mutations and epigenetic deregulation of its major regulators is known to cause resistance of 
melanoma to therapeutic agents, including the conventional chemotherapeutic drug dacarbazine 
and the Food and Drug Administration-approved mutant BRAF inhibitors vemurafenib and 
dabrafenib, the role of extracellular stimuli of the pathway, such as insulin, in drug resistance 
of melanoma remains less understood.
Objective: To investigate the effect of insulin on the response of melanoma cells to dacarbazine, 
and in particular, the effect of insulin on the response of melanoma cells carrying the BRAFV600E 
mutation to mutant BRAF inhibitors. An additional aim was to define the role of the PI3K/Akt 
pathway in the insulin-triggered drug resistance.
Methods: The effect of insulin on cytotoxicity induced by dacarbazine or the mutant BRAF 
inhibitor PLX4720 was tested by pre-incubation of melanoma cells with insulin. Cytotoxicity 
was determined by the MTS assay. The role of the PI3K/Akt pathway in the insulin-triggered 
drug resistance was examined using the PI3K inhibitor LY294002 and the PI3K and mammalian 
target of rapamycin dual inhibitor BEZ-235. Activation of the PI3K/Akt pathway was monitored 
by Western blot analysis of phosphorylated levels of Akt.
Results: Recombinant insulin attenuated dacarbazine-induced cytotoxicity in both wild-type 
BRAF and BRAFV600E melanoma cells, whereas it also reduced killing of BRAFV600E melanoma 
cells by PLX4720. Nevertheless, the protective effect of insulin was abolished by the PI3K and 
mTOR dual inhibitor BEZ-235 or the PI3K inhibitor LY294002.
Conclusion: Insulin attenuates the therapeutic efficacy of dacarbazine and PLX4720 in mela-
noma cells, which is mediated by activation of the PI3K/Akt pathway and can be overcome 
by PI3K inhibitors.
Keywords: insulin, PI3K/Akt, melanoma, drug resistance, DTIC, BRAF inhibitors
Introduction
Melanoma is one of the most aggressive cancers. Although early stages of melanoma 
can be removed by surgery with high patient survival rates, metastatic melanoma has 
poor prognosis. Despite recent progress in the treatment of late-stage melanoma, and in 
particular, the advance in development of novel targeted therapy and immunotherapy 
approaches, the overall outcome of patients with metastatic melanoma remains poor.1 
The median survival period of these patients is about 6 to 10 months, and the 5-year 
survival rate is lower than 20%.2,3 Therefore, it is of paramount importance to improve the 
therapeutic efficacy of treatments for metastatic melanoma. This could be achieved either 





by improving already existing Food and Drug Administration-
approved drugs or by developing novel therapeutic agents.
Dacarbazine (DTIC) is the most commonly used chemo-
therapeutic drug in the treatment of metastatic melanoma.4 
However, only 5%–10% of patients benefit from administra-
tion of DTIC.5 The mechanisms responsible for resistance of 
melanoma cells to DTIC remain undefined, but combinations 
of DTIC with other agents have been attempted to increase 
the therapeutic efficacy. A Phase III clinical trial showed that 
DTIC in combination with cisplatin or vindesine increased 
the response rate to 20%–40%.6 However, disease-free and 
overall survival rates were not increased.7 The combination of 
DTIC with interleukin-2 or tumor-necrosis-factor-α improved 
the response rate, but adverse effects were also increased.8
Cancer-targeted therapy is based on an understanding 
of the roles of key molecules in the cancer pathogenesis. 
 Activating BRAF mutations that drive melanoma cell survival 
and proliferation are found in about 60% of melanomas. 
The most common mutation in melanoma is a glutamic 
acid substitution for valine at position 600 (BRAFV600E).9,10 
 Targeting mutant BRAF using small molecule inhibitors, such 
as vemurafenib and dabrafenib has achieved unprecedented 
responses in metastatic melanoma patients.11–13 However, 
complete remission is rare and a proportion of mutant BRAF 
melanomas are less responsive to the inhibitors, indicative of 
inherent resistance.11,14–16 Moreover, the durations of responses 
are commonly limited, with most patients relapsing within 
1 year, which is indicative of development of acquired drug 
resistance.11,14–16 Multiple mechanisms have been shown to 
contribute to the resistance of mutant BRAF melanomas to 
BRAF inhibitors.11,14–16 These include those mechanisms lead-
ing to insufficient inhibition of RAF/MEK/ERK signaling and 
those promoting melanoma cell survival and proliferation 
alternative to the RAF/MEK/ERK pathway, such as increased 
activation of the PI3K/Akt or NF-κB pathways.17–25 Indeed, 
combinations of RAF inhibitors and inhibitors of MEK such 
as trametinib to further inhibit MEK/ERK signaling have 
yielded promising results in clinical trials.26–28 Co-targeting 
the PI3K/Akt and RAF/MEK/ERK pathways is also being 
evaluated in early clinical studies.23,29
Insulin is known to activate the PI3K/Akt pathway and 
thus increases carcinogenesis.30,31 Besides gene mutations of 
the major components of the pathway, extracellular stimuli 
such as insulin and insulin-like growth factor 1 (IGF-1) 
also enhance PI3K/Akt signaling and cause drug resistance. 
Indeed, in many types of cancer cells, insulin induces 
resistance to chemotherapeutic drugs and may contribute 
to poor prognosis, particularly in patients with obesity and 
type II diabetes.32,33 However, the role of insulin in mela-
noma cell resistance to chemotherapy and targeted therapy 
remains less understood. Here we show that insulin attenuates 
the therapeutic efficacy of DTIC and the BRAF inhibitor 
PLX4720 in melanoma cells, and that this is mediated by 
activation of the PI3K/Akt pathway and can be overcome by 
PI3K inhibitors and dual inhibitors of PI3K and mammalian 
target of rapamycin (mTOR).
Materials and methods
cell culture and reagents
The mouse melanoma cell line B16 and the human mela-
noma cell line Mel-RMu described previously were cultured 
in  Dulbecco’s Modified Eagle’s Medium containing 5% 
fetal calf serum.34 Antibodies against Akt and phospho-Akt 
(Ser473) were purchased from Cell Signaling Technology 
(Danvers, MA, USA). The PI3K inhibitor LY294002 was 
from Calbiochem (Merck KGaA, Darmstadt, Germany). 
The dual inhibitor PI3K and mTOR, BEZ-235, was from 
Selleckchem (Houston, TX, USA). The antibodies against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
from Ambion (Life Technologies, Carlsbad, CA, USA). 
The BRAF inhibitor PLX4720 was from Selleckchem. 
Dacarbazine was purchased from Sigma-Aldrich (St Louis, 
MO, USA).
cell viability
Cell viability was determined by MTS assay using Celltiter 
96 aqueous one solution cell proliferation assay kit according 
to the manufacturer’s instructions (Promega Corporation, 
Madison, WI, USA) as described previously.35 In brief, cells 
were seeded at 5,000 cells/well onto flat-bottomed 96-well 
culture plates and allowed to grow for 24 hours followed by 
the desired treatment duration. Cells were then labeled with 
the VisionBlueTM reagent and detected by Synergy 2TM multi-
detection microplate reader (Biotek, Winooski, VT, USA).
immunoblotting
Immunoblotting was carried out as described previously.35 
Labeled bands were detected by Luminata Crescendo 
Western horseradish peroxidase substrate (EMD Millipore, 
Billerica, MA, USA) and images were captured and the 
intensity of the bands was quantitated using an ImageReader 
LAS-4000 (Fujifilm Corporation, Tokyo, Japan).
statistical analysis
Statistical analysis was performed using JMP Statistics 
Made VisualTM software (SAS Institute, Cary, NC, USA). 
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Student’s t-test was used to assess differences in the values 
of different experimental groups. P-values less than 0.05 
were considered statistically significant.
Results
insulin protects melanoma cells against 
DTic-mediated cytotoxicity
We examined the cytotoxic effect of DTIC on the mouse 
melanoma cell line B16 that harbored wild-type BRAF 
and the human melanoma cell line Mel-RMu that carried 
BRAFV600E by treating the cells with the drug at increasing 
concentrations for 24 hours.36,37 As shown in Figure 1, DTIC 
reduced viability of B16 and Mel-RMu cells in a dose-
dependent manner irrespective of their BRAF mutational 
status. Since DTIC at 25 µg/mL inhibited viability of both 
B16 and Mel-RMu cells by approximately 50% (Figure 1). 
This concentration was chosen for assays hereafter.
To examine whether insulin protects melanoma cells 
from cytotoxicity induced by DTIC, B16 and Mel-RMu cells 
were pre-treated with insulin at a range of concentrations for 
15 minutes before the addition of DTIC at 25 µg/mL for a 
further 24 hours. As shown in Figure 2, even when used at 
250 nM, insulin significantly protected Mel-RMu and, to a 
lesser extent, B16 cells from DTIC-mediated cytotoxicity. 
The survival rates of Mel-RMu and B16 cells were increased 






















Figure 1 cytotoxicity of DTic towards melanoma cells.
Notes: B16 mouse melanoma cells and Mel-rMu human melanoma cells were 
treated with DTic at indicated concentrations for 24 hours. cell viability was 
measured by MTs assays and expressed as a relative value of control. The data 
shown are the mean ± standard error of three individual experiments.
Abbreviations: DTic, dacarbazine; MTs, cellTiter 96® aqueous one solution cell 
proliferation.
increased concentrations did not afford any further protection 
against DTIC. This may be due to negative cooperativity of 
binding of insulin to its receptor.38 Regardless, these results 
suggest that circulating insulin in melanoma patients, par-
ticularly melanoma patients with obesity, may attenuate the 
therapeutic efficacy of chemotherapeutic drugs.
insulin protects BRAFV600E melanoma cells 
from cytotoxicity induced by the mutant 
BraF inhibitor PlX4720
Since Mel-RMu cells are known to harbor BRAFV600E and 
are sensitive to the mutant BRAF inhibitor PLX4720,24 we 
examined whether insulin similarly protects the cells from 
PLX4720-mediated cytotoxicity. B16 mouse melanoma cells 
that carry wild-type BRAF and are not sensitive to mutant 
BRAF inhibitors were excluded from studies using PLX4720.39 
Indeed, insulin at 250 nM significantly inhibited reduction in 
viability of Mel-RMu cells induced by PLX4720 (Figure 3).
insulin activates the Pi3K/akt signalling 
pathway in melanoma cell lines
Aberrant activation of the PI3K/Akt pathway is known to 
confer resistance of melanoma cells to therapeutic drugs.30,31 
We examined whether exposure of melanoma cells to insulin 
results in activation of PI3K/Akt signaling. As anticipated, 
exposure to insulin increased the levels of phosphorylated 
Akt in both B16 and Mel-RMu cells (Figure 4), indicating 
increased activation of the PI3K/Akt pathway.
inhibition of the Pi3K/akt pathway 
reverses protection of melanoma cells 
against DTic and/or PlX4720 by insulin
To confirm the role of the PI3K/Akt pathway in insulin-
 mediated protection of melanoma cells from therapeutic 
drugs, we pre-treated B16 and Mel-RMu cells with the 
PI3K and mTOR dual inhibitor BEZ-235 before the addi-
tion of insulin (250 nM) followed by DTIC. While BEZ-
235 abolished the increase in activation of Akt induced by 
insulin in both B16 and Mel-RMu cells (Figure 5A), it also 
diminished insulin-mediated protection against cytotoxic-
ity induced by DTIC (Figure 5B). Similarly, BEZ-235 also 
significantly inhibited protection of Mel-RMu cells against 
PLX4720 by insulin (Figure 5C). Of note, BEZ-235 enhanced 
cytotoxicity triggered by PLX4720 alone in Mel-RMu cells 
(Figure 5C), consistent with previous reports that inhibition 
of the PI3K/Akt pathway sensitizes mutant BRAF melanoma 
cells to BRAF inhibitors.40,41
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Figure 2 insulin protects melanoma cells against DTic.
Notes: B16 (upper panel) and Mel-rMu (lower panel) cells with or without pretreatment with insulin at indicated concentrations for 15 minutes were treated with DTic 
(25 µg/ml) for a further 24 hours. cell viability was measured by MTs assays. The data shown are the mean ± standard error of three individual experiments (*P,0.01, 
student’s t-test).



























Figure 3 insulin protects BraFV600e melanoma cells against the BraF inhibitor 
PlX4720.
Notes: Mel-rMu cells with or without pretreatment with insulin (250 nM) for 
15 minutes were treated with PlX4720 (5 µM) for a further 24 hours. cell viability 
was measured by MTs assays. The data shown are the mean ± standard error of 
three individual experiments (*P,0.01, student’s t-test).
Abbreviations: MTs, cellTiter 96® aqueous one solution cell proliferation; BraF, 
v-raf murine sarcoma viral oncogene homolog B1.
We also examined whether the PI3K inhibitor 
LY294002 similarly reverses protection of melanoma cells 
against therapeutic drugs by insulin. As shown in Figure 6A, 
LY294002 abolished the insulin-triggered increase in activa-
tion of Akt in B16 and Mel-RMu cells. Moreover, similar 
to BEZ-235, it also significantly inhibited insulin-mediated 
protection of B16 and Mel-RMu cells from DTIC, and pro-
tection of Mel-RMu cells from PLX4720 (Figure 6B and C). 
Together, these results suggest that activation of the PI3K/Akt 
pathways plays a predominant role in protection of melanoma 
cells from therapeutic drugs by insulin.
Discussion
Resistance of melanoma cells to therapeutic drugs is a major 
obstacle in the quest for curative treatment of melanoma. 
The response rate to the conventional chemotherapeutic drug 
DTIC is only 5%–10%,5 whereas approximately 50%–60% 
of patients with mutant BRAF metastatic melanomas 
initially respond to the BRAF inhibitor vemurafenib or 
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Figure 4 insulin activates the Pi3K/akt in melanoma cells.
Notes: Whole cell lysates from B16 and Mel-rMu cells with or without treatment 
with insulin (250 nM) for 15 minutes were subjected to Western blot analysis of 
phosphorylated akt, akt, and gaPDh (as a loading control). The data shown are 
representative of three individual experiments.






























































































































































Figure 5 The Pi3K and mTOr dual inhibitor BeZ-235 reverses protection of melanoma cells against DTic and/or PlX4720 by insulin.
Notes: (A) Whole cell lysates from B16 and Mel-rMu cells with or without pretreatment with BeZ-235 (50 nM) for 1 hour followed by exposure to insulin (250 nM) for 
a further 15 minutes were subjected to Western blot analysis of phosphorylated akt, akt, and gaPDh (as a loading control). The data shown are representative of three 
individual experiments. (B) B16 (upper panel) and Mel-rMu (lower panel) cells were pretreated with BeZ-235 (50 nM) for 1 hour before the addition of insulin (250 nM) 
for 15 minutes followed by exposure to DTic (25 µg/ml) for a further 24 hours. cell viability was measured by MTs assays. The data shown are the mean ± standard error 
of three individual experiments (*P,0.01, student’s t-test). (C) Mel-rMu cells were pretreated with BeZ-235 (50 nM) for 1 hour before the addition of insulin (250 nM) for 
15 minutes followed by exposure to PlX4720 (5 µM) for a further 24 hours. cell viability was measured by MTs assays. The data shown are the mean ± standard error of 
three individual experiments (*P,0.01, student’s t-test).
Abbreviations: DTic, dacarbazine; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; akt, protein kinase B; MTs, cellTiter 96® aqueous one solution cell proliferation.
dabrafenib.11,14–16 Nevertheless, durations of responses to 
BRAF inhibitors are commonly limited, with most patients 
relapsing within 1 year.12,15,16 One of the mechanisms 
responsible for resistance of melanoma cells to therapeutic 
drugs is aberrant activation of the PI3K/Akt pathway due to 
genetic mutations and/or epigenetic deregulation of its major 
regulators.42,43 However, the role of extracellular stimuli that 
can activate the pathway in drug-resistant melanoma cells 
remains less well understood. In this report, we demonstrated 
that the addition of insulin enhanced resistance of cultured 
melanoma cells to DTIC. In addition, we showed that insulin 
also protected mutant BRAF melanoma cells from the BRAF 
inhibitor PLX4720. These results suggest that elevated 
levels of circulating insulin in melanoma patients, such as 
those with obesity and type II diabetes, may compromise 
their responses to conventional chemotherapeutic drugs 
and agents targeting pro-survival pathways, thus leading to 
poor prognosis.
Our study showed that insulin increased activation of 
the PI3K/Akt pathway, and that inhibition of the pathway 
reversed insulin-mediated protection against DTIC in both 
wild-type BRAF B16 cells and BRAFV600E Mel-RMu cells. 
In addition, the results also demonstrated that inhibition of 
cytotoxicity of PLX4720 by insulin in Mel-RMu cells were 
also abolished when PI3K/Akt signaling was blocked. These 
results indicate that activation of the PI3K/Akt pathway 





plays an essential role in drug resistance of melanoma cells 
induced by insulin. The PI3K/Akt pathway is a well-known 
pro-survival pathway in many cancers.30,31 The pathway is 
activated by various growth factors and regulates a broad 
range of targets that regulate cell survival, proliferation, and 
resistance to therapeutic agents.31 Our results showing that 
insulin activates the PI3K/Akt pathway leading to drug resis-
tance reinforce the importance of extracellular stimuli of the 
pathway in protection of melanoma cells against treatment. 
Insulin is known to bind to insulin receptors, IGF-1 receptors, 
and insulin/IGF-1 hybrid receptors to activate PI3K/Akt.40 
In addition, it can inhibit the production of IGF-binding 
proteins and therefore increase blood levels of IGF-1, a 
stronger anti-apoptotic molecule than insulin. Indeed, blood 
levels of IGF-1 have been reported to positively associate 
with the incidence of melanoma while blood levels of IGF-
binding proteins are inversely associated.23 IGF-1 has been 
demonstrated to increase survival and growth of melanoma 
cells via activation of MAPK and PI3K/Akt pathways.44 It is 
highly possible that IGF-1 can also cause drug resistance to 
chemotherapeutic agents in melanoma cells. In addition to 
insulin, a number of other growth factors that may exist in a 
melanoma microenvironment, such as fibroblast growth fac-
tor, hepatocyte growth factor, and epithelial growth factor, are 
conceivably involved in drug resistance of melanoma cells, 
as they can similarly stimulate PI3K/Akt signaling and other 
survival pathways such as the MEK/ERK pathway.
DTIC is a standard drug that is commonly used in the 
treatment of metastatic melanoma. Although the initial 
response rate is low, the drug is not out of date.4,5 Our 
results showing that activation of the PI3K/Akt pathway by 
insulin protects melanoma cells from DTIC could partially 
explain the low response rate to DTIC, and suggest that the 
combinatorial approaches with inhibitors of the PI3K/Akt 
pathway and DTIC may increase the therapeutic efficacy. 
Combinations of DTIC with other agents have not been 
satisfactory.6,8
It is of note that the PI3K inhibitor LY294002 and the 
PI3K and mTOR dual inhibitor BEZ-235 decreased the effect 
of insulin on protection of melanoma cells against therapeutic 
drugs to a similar extent, suggesting that the protective effect 
of insulin is mainly mediated by PI3K, although mTOR may 
also play a role. Various inhibitors of the PI3K/Akt pathway 
and dual inhibitors of PI3K and mTOR are in clinical and/
or preclinical studies, including BEZ-235.45 Our results sup-
port combinations of BEZ-235 and other PI3K inhibitors 
with clinically available agents for further evaluation. One 
of the suitable conditions for such a regime is in the case of 





























































































































































Figure 6 The Pi3K inhibitor lY294002 reverses protection of melanoma cells against DTic and/or PlX4720 by insulin.
Notes: (A) Whole cell lysates from B16 and Mel-rMu cells with or without pretreatment with lY294002 (20 µM) for 1 hour followed by exposure to insulin (250 nM) for 
a further 15 minutes were subjected to Western blot analysis of phosphorylated akt, akt, and gaPDh (as a loading control). The data shown are representative of three 
individual experiments. (B) B16 (upper panel) and Mel-rMu (lower panel) cells were pretreated with lY294002 (20 µM) for 1 hour before the addition of insulin (250 nM) 
for 15 minutes followed by exposure to DTic (25 µg/ml) for a further 24 hours. cell viability was measured by MTs assays. The data shown are the mean ± standard error 
of three individual experiments (*P,0.01, student’s t-test). (C) Mel-rMu cells were pretreated with lY294002 (20 µM) for 1 hour before the addition of insulin (250 nM) 
for 15 minutes followed by exposure to PlX4720 (5 µM) for a further 24 hours. cell viability was measured by MTs assays. The data shown are the mean ± standard error 
of three individual experiments (*P,0.01, student’s t-test).
Abbreviations: DTic, dacarbazine; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; akt, protein kinase B; MTs, cellTiter 96® aqueous one solution cell proliferation.
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patients with elevated serum levels of insulin, such as those 
with obesity and type II diabetes.
In summary, we have provided evidence that insulin 
protects melanoma cells from the chemotherapeutic drug 
DTIC and BRAF inhibitors. In addition, we have shown that 
insulin-induced drug resistance is primarily due to activation 
of the PI3K/Akt pathway. Our results indicate that combi-
nations of inhibitors of the PI3K/Akt pathway and DTIC or 
BRAF inhibitors may be useful to improve the therapeutic 
efficacy in the treatment of melanoma, in particular, in 
patients with obesity and type II diabetes who have elevated 
serum insulin levels.
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